KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Profit After Tax (2016 - 2025)

Teva Pharmaceutical Industries' Profit After Tax history spans 10 years, with the latest figure at $480.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax rose 274.55% year-over-year to $480.0 million, compared with a TTM value of $1.4 billion through Dec 2025, up 185.76%, and an annual FY2025 reading of $1.4 billion, up 171.98% over the prior year.
  • Profit After Tax for Q4 2025 was $480.0 million at Teva Pharmaceutical Industries, up from $433.0 million in the prior quarter.
  • The five-year high for Profit After Tax was $480.0 million in Q4 2025, with the low at -$1.3 billion in Q4 2022.
  • Average Profit After Tax over 5 years is -$142.2 million, with a median of -$38.0 million recorded in 2022.
  • Year-over-year, Profit After Tax surged 316.98% in 2021 and then crashed 1336.36% in 2022.
  • Tracing TEVA's Profit After Tax over 5 years: stood at -$152.0 million in 2021, then crashed by 755.92% to -$1.3 billion in 2022, then surged by 135.74% to $465.0 million in 2023, then crashed by 159.14% to -$275.0 million in 2024, then skyrocketed by 274.55% to $480.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Profit After Tax are $480.0 million (Q4 2025), $433.0 million (Q3 2025), and $282.0 million (Q2 2025).